Recent News

• 03.06.2025 - Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
• 02.27.2025 - Enveric Biosciences CEO Issues Letter to Shareholders
• 02.26.2025 - Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds [Microdose]
• 02.26.2025 - EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD [Benzinga]
• 02.25.2025 - Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
• 02.04.2025 - A New Horizon in Joint Disease Treatment: Enveric Biosciences and Restoration Biologics Forge Licensing Agreements [Microdose]
• 02.04.2025 - Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease [Benzinga]
• 02.04.2025 - Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease [Benzinga]
• 02.04.2025 - Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
• 02.04.2025 - Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Recent Filings

• 03.06.2025 - 8-K Current report
• 02.26.2025 - EX-99.1 EX-99.1
• 02.26.2025 - 8-K Current report
• 02.05.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.04.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.04.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors